{"protocolSection": {"identificationModule": {"nctId": "NCT01096017", "orgStudyIdInfo": {"id": "D589LC00002"}, "organization": {"fullName": "AstraZeneca", "class": "INDUSTRY"}, "briefTitle": "To Investigate the Relative Efficacy of Terbutaline Turbuhaler\u00ae and Salbutamol Pressurized Metered Dose Inhaler (pMDI) a Single Blind Study", "officialTitle": "A Study to Investigate the Relative Efficacy of Terbutaline Turbuhaler\u00ae 0.4 mg and Salbutamol Pressurized Metered Dose Inhaler (pMDI) 200 \u03bcg - a Single Blind, Single Dose, Randomized, Crossover, Phase III Study in Japanese Adult Asthma Patients"}, "statusModule": {"statusVerifiedDate": "2012-07", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2010-03"}, "primaryCompletionDateStruct": {"date": "2010-04", "type": "ACTUAL"}, "completionDateStruct": {"date": "2010-04", "type": "ACTUAL"}, "studyFirstSubmitDate": "2010-03-19", "studyFirstSubmitQcDate": "2010-03-29", "studyFirstPostDateStruct": {"date": "2010-03-30", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2011-10-03", "resultsFirstSubmitQcDate": "2012-07-27", "resultsFirstPostDateStruct": {"date": "2012-08-31", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2012-07-27", "lastUpdatePostDateStruct": {"date": "2012-08-31", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "AstraZeneca", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "This is a single blind, single dose, crossover study to investigate the relative efficacy of terbutaline Turbuhaler\u00ae 0.4 mg in relation to salbutamol pressurized Metered Dose Inhaler (pMDI) 200 \u03bcg in Japanese adult asthmatic patients.The secondary objective of this study is to investigate safety of terbutaline Turbuhaler\u00ae 0.4 mg in Japanese adult asthma patients by means of adverse events (AEs) and vital signs (blood pressure, pulse rate). The subject population includes Japanese patients (16 years of age or older) with asthma who need treatment with inhaled Glucocorticosteroids (ICS)."}, "conditionsModule": {"conditions": ["Asthma"], "keywords": ["Terbutaline", "Turbuhaler", "Efficacy", "Asthma", "Japanese", "salbutamol", "Bricanyl"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "CROSSOVER", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "SINGLE", "whoMasked": ["PARTICIPANT"]}}, "enrollmentInfo": {"count": 24, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "1", "type": "EXPERIMENTAL", "description": "Terbutaline Turbuhaler\u00ae 0.4mg + pMDI placebo pMDI \u21d2salbutamol pMDI 200 \u03bcg +placebo Turbuhaler\u00ae", "interventionNames": ["Drug: Terbutaline Turbuhaler\u00ae", "Other: pMDI placebo pMDI", "Other: Placebo Turbuhaler\u00ae"]}, {"label": "2", "type": "EXPERIMENTAL", "description": "salbutamol pMDI 200 \u03bcg +placebo Turbuhaler\u00ae \u21d2Terbutaline Turbuhaler\u00ae 0.4mg + pMDI placebo pMDI", "interventionNames": ["Drug: Salbutamol pMDI", "Other: pMDI placebo pMDI", "Other: Placebo Turbuhaler\u00ae"]}], "interventions": [{"type": "DRUG", "name": "Terbutaline Turbuhaler\u00ae", "description": "0.4 mg, inhalation, single dose", "armGroupLabels": ["1"], "otherNames": ["Bricanyl Turbuhaler"]}, {"type": "DRUG", "name": "Salbutamol pMDI", "description": "200 \u03bcg, inhalation, single dose", "armGroupLabels": ["2"], "otherNames": ["Saltanol"]}, {"type": "OTHER", "name": "pMDI placebo pMDI", "description": "Placebo pMDI 2 inhalations", "armGroupLabels": ["1", "2"]}, {"type": "OTHER", "name": "Placebo Turbuhaler\u00ae", "description": "Placebo Turbuhaler 1 inhalation", "armGroupLabels": ["1", "2"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "FEV1 (Forced Expiratory Volume in 1 Second) Area Under Curve (AUC) 0-4 Hours After Drug Inhalation", "description": "FEV1 (Forced Expiratory Volume in 1 second) AUC 0-4 hours after drug inhalation", "timeFrame": "At two visits during a maximum of 15 days. FEV1 timepoints: all time points t=5, 15, 30, 60, 120, 180 and 240 minutes."}], "secondaryOutcomes": [{"measure": "FEV1 (Forced Expiratory Volume in 1 Second) at 5 Minutes After Inhalations of Study Drug as Percentage of Pre-dose", "description": "percent of pre-dose (ratio)", "timeFrame": "At two visits during a maximum of 15 days"}, {"measure": "FEV1 (Forced Expiratory Volume in 1 Second) at 15 Minutes After Inhalations of Study Drug as Percentage of Pre-dose", "description": "percent of pre-dose (ratio)", "timeFrame": "At two visits during a maximum of 15 days"}, {"measure": "FEV1 (Forced Expiratory Volume in 1 Second) at 30 Minutes After Inhalations of Study Drug as Percentage of Pre-dose", "description": "percent of pre-dose (ratio)", "timeFrame": "At two visits during a maximum of 15 days"}, {"measure": "FEV1 (Forced Expiratory Volume in 1 Second) at 60 Minutes After Inhalations of Study Drug as Percentage of Pre-dose", "description": "percent of pre-dose (ratio)", "timeFrame": "At two visits during a maximum of 15 days"}, {"measure": "FEV1 (Forced Expiratory Volume in 1 Second) at 120 Minutes After Inhalations of Study Drug as Percentage of Pre-dose", "description": "percent of pre-dose (ratio)", "timeFrame": "At two visits during a maximum of 15 days"}, {"measure": "FEV1 (Forced Expiratory Volume in 1 Second) at 180 Minutes After Inhalations of Study Drug as Percentage of Pre-dose", "description": "percent of pre-dose (ratio)", "timeFrame": "At two visits during a maximum of 15 days"}, {"measure": "FEV1 (Forced Expiratory Volume in 1 Second) at 240 Minutes After Inhalations of Study Drug as Percentage of Pre-dose", "description": "percent of pre-dose (ratio)", "timeFrame": "At two visits during a maximum of 15 days"}, {"measure": "Maximum % Change in FEV1 (Forced Expiratory Volume in 1 Second) Within 4 Hours After Drug Inhalation", "description": "percent of pre-dose (ratio)", "timeFrame": "At two visits during a maximum of 15 days"}, {"measure": "Time to Peak FEV1 (Forced Expiratory Volume in 1 Second) Within 4 Hours After Drug Inhalation", "description": "Time to peak measurement of FEV1 (min)", "timeFrame": "At two visits during a maximum of 15 days"}, {"measure": "Number of Patients With % Change in FEV1 (Forced Expiratory Volume in 1 Second) >15% Within 4 Hours After Drug Inhalation", "description": "Number of patients with % change in FEV1 \\>15% within 4 hours after drug inhalation.", "timeFrame": "At two visits during a maximum of 15 days"}, {"measure": "Time to Change More Than or Equal to 15% (Time to Onset Response) Within 4 Hours After Drug Inhalation", "description": "Time to change more than or equal to 15% (time to onset response) within 4 hours after drug inhalation", "timeFrame": "At two visits during a maximum of 15 days"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* On ICS for at least 3 months from Visit 2 and with a prescribed constant dose during the 4 weeks prior to Visit 2\n* Forced Expiratory Volume in 1 Second (FEV1) of at least 50 % of predicted normal value pre-bronchodilator\n* Reversible airway obstruction according to reversibility test performed at Visit 2, defined as an increase in Forced Expiratory Volume in 1 Second (FEV1) \u226512% relative baseline at 15-30 minutes after inhalation of in total 400 \u03bcg salbutamol\n\nExclusion Criteria:\n\n* Treatment with oral, parenteral or rectal GCS (Glucocorticosteroids)within 4 weeks or depot parenteral GCS (Glucocorticosteroids) within 3 months prior to Visit 2.\n* Change in prescribed asthma medication due to exacerbation of asthma within 4 weeks prior to Visit 2 or being hospitalized due to exacerbation of asthma within 8 weeks prior to Visit 2.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "16 Years", "stdAges": ["CHILD", "ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Tomas Andersson, MD", "affiliation": "AstraZeneca", "role": "STUDY_CHAIR"}], "locations": [{"facility": "Research Site", "city": "Tokyo", "country": "Japan", "geoPoint": {"lat": 35.6895, "lon": 139.69171}}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "37 participants enrolled; 13 excluded (9 due to eligibility criteria not fulfilled and 4 for other reasons)", "recruitmentDetails": "Participants recruited at one clinic in Tokyo, Japan, between March and April 2010", "groups": [{"id": "FG000", "title": "Salbutamol First, Then Terbutaline", "description": "Salbutamol pMDI 200 \u03bcg +placebo Turbuhaler\u00ae \u21d2Terbutaline Turbuhaler\u00ae 0.4mg + pMDI placebo pMDI"}, {"id": "FG001", "title": "Terbutaline First, Then Salbutamol", "description": "Terbutaline Turbuhaler\u00ae 0.4mg + pMDI placebo pMDI \u21d2Salbutamol pMDI 200 \u03bcg +placebo Turbuhaler\u00ae"}], "periods": [{"title": "Treatment Period 1", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "12"}, {"groupId": "FG001", "numSubjects": "12"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "12"}, {"groupId": "FG001", "numSubjects": "12"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}]}]}, {"title": "Washout 1 - 14 Days", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "12"}, {"groupId": "FG001", "numSubjects": "12"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "12"}, {"groupId": "FG001", "numSubjects": "12"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}]}]}, {"title": "Treatment Period 2", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "12"}, {"groupId": "FG001", "numSubjects": "12"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "11"}, {"groupId": "FG001", "numSubjects": "11"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}]}], "dropWithdraws": [{"type": "Eligibility criteria not fulfilled", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "All Study Participants"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "24"}]}], "measures": [{"title": "Age Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "41.7", "spread": "7.4"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "17"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "7"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "FEV1 (Forced Expiratory Volume in 1 Second) Area Under Curve (AUC) 0-4 Hours After Drug Inhalation", "description": "FEV1 (Forced Expiratory Volume in 1 second) AUC 0-4 hours after drug inhalation", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Full Range", "unitOfMeasure": "milliLiters x minutes", "timeFrame": "At two visits during a maximum of 15 days. FEV1 timepoints: all time points t=5, 15, 30, 60, 120, 180 and 240 minutes.", "groups": [{"id": "OG000", "title": "Salbutamol pMDI", "description": "200 \u03bcg, inhalation, single dose"}, {"id": "OG001", "title": "Terbutaline Turbuhaler\u00ae", "description": "0.4 mg, inhalation, single dose"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "22"}, {"groupId": "OG001", "value": "22"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "617.56", "lowerLimit": "352.57", "upperLimit": "974.45"}, {"groupId": "OG001", "value": "634.64", "lowerLimit": "356.68", "upperLimit": "1016.46"}]}]}]}, {"type": "SECONDARY", "title": "FEV1 (Forced Expiratory Volume in 1 Second) at 5 Minutes After Inhalations of Study Drug as Percentage of Pre-dose", "description": "percent of pre-dose (ratio)", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Full Range", "unitOfMeasure": "Percentage of Pre-Dose FEV1", "timeFrame": "At two visits during a maximum of 15 days", "groups": [{"id": "OG000", "title": "Salbutamol pMDI", "description": "200 \u03bcg, inhalation, single dose"}, {"id": "OG001", "title": "Terbutaline Turbuhaler\u00ae", "description": "0.4 mg, inhalation, single dose"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "22"}, {"groupId": "OG001", "value": "22"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "115.58", "lowerLimit": "102.80", "upperLimit": "137.95"}, {"groupId": "OG001", "value": "112.80", "lowerLimit": "100.00", "upperLimit": "134.85"}]}]}]}, {"type": "SECONDARY", "title": "FEV1 (Forced Expiratory Volume in 1 Second) at 15 Minutes After Inhalations of Study Drug as Percentage of Pre-dose", "description": "percent of pre-dose (ratio)", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Full Range", "unitOfMeasure": "Percentage of Pre-Dose FEV1", "timeFrame": "At two visits during a maximum of 15 days", "groups": [{"id": "OG000", "title": "Salbutamol pMDI", "description": "200 \u03bcg, inhalation, single dose"}, {"id": "OG001", "title": "Terbutaline Turbuhaler\u00ae", "description": "0.4 mg, inhalation, single dose"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "22"}, {"groupId": "OG001", "value": "22"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "118.15", "lowerLimit": "105.11", "upperLimit": "142.16"}, {"groupId": "OG001", "value": "115.69", "lowerLimit": "103.27", "upperLimit": "138.59"}]}]}]}, {"type": "SECONDARY", "title": "FEV1 (Forced Expiratory Volume in 1 Second) at 30 Minutes After Inhalations of Study Drug as Percentage of Pre-dose", "description": "percent of pre-dose (ratio)", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Full Range", "unitOfMeasure": "Percentage of Pre-Dose FEV1", "timeFrame": "At two visits during a maximum of 15 days", "groups": [{"id": "OG000", "title": "Salbutamol pMDI", "description": "200 \u03bcg, inhalation, single dose"}, {"id": "OG001", "title": "Terbutaline Turbuhaler\u00ae", "description": "0.4 mg, inhalation, single dose"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "22"}, {"groupId": "OG001", "value": "22"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "119.42", "lowerLimit": "103.28", "upperLimit": "147.32"}, {"groupId": "OG001", "value": "117.02", "lowerLimit": "99.59", "upperLimit": "139.83"}]}]}]}, {"type": "SECONDARY", "title": "FEV1 (Forced Expiratory Volume in 1 Second) at 60 Minutes After Inhalations of Study Drug as Percentage of Pre-dose", "description": "percent of pre-dose (ratio)", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Full Range", "unitOfMeasure": "Percentage of Pre-Dose FEV1", "timeFrame": "At two visits during a maximum of 15 days", "groups": [{"id": "OG000", "title": "Salbutamol pMDI", "description": "200 \u03bcg, inhalation, single dose"}, {"id": "OG001", "title": "Terbutaline Turbuhaler\u00ae", "description": "0.4 mg, inhalation, single dose"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "22"}, {"groupId": "OG001", "value": "22"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "120.28", "lowerLimit": "102.19", "upperLimit": "149.19"}, {"groupId": "OG001", "value": "118.11", "lowerLimit": "102.86", "upperLimit": "144.40"}]}]}]}, {"type": "SECONDARY", "title": "FEV1 (Forced Expiratory Volume in 1 Second) at 120 Minutes After Inhalations of Study Drug as Percentage of Pre-dose", "description": "percent of pre-dose (ratio)", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Full Range", "unitOfMeasure": "Percentage of Pre-Dose FEV1", "timeFrame": "At two visits during a maximum of 15 days", "groups": [{"id": "OG000", "title": "Salbutamol pMDI", "description": "200 \u03bcg, inhalation, single dose"}, {"id": "OG001", "title": "Terbutaline Turbuhaler\u00ae", "description": "0.4 mg, inhalation, single dose"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "22"}, {"groupId": "OG001", "value": "22"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "119.54", "lowerLimit": "97.45", "upperLimit": "149.73"}, {"groupId": "OG001", "value": "119.79", "lowerLimit": "103.27", "upperLimit": "150.21"}]}]}]}, {"type": "SECONDARY", "title": "FEV1 (Forced Expiratory Volume in 1 Second) at 180 Minutes After Inhalations of Study Drug as Percentage of Pre-dose", "description": "percent of pre-dose (ratio)", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Full Range", "unitOfMeasure": "Percentage of Pre-Dose FEV1", "timeFrame": "At two visits during a maximum of 15 days", "groups": [{"id": "OG000", "title": "Salbutamol pMDI", "description": "200 \u03bcg, inhalation, single dose"}, {"id": "OG001", "title": "Terbutaline Turbuhaler\u00ae", "description": "0.4 mg, inhalation, single dose"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "22"}, {"groupId": "OG001", "value": "22"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "116.68", "lowerLimit": "92.70", "upperLimit": "142.70"}, {"groupId": "OG001", "value": "118.48", "lowerLimit": "100.68", "upperLimit": "146.06"}]}]}]}, {"type": "SECONDARY", "title": "FEV1 (Forced Expiratory Volume in 1 Second) at 240 Minutes After Inhalations of Study Drug as Percentage of Pre-dose", "description": "percent of pre-dose (ratio)", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Full Range", "unitOfMeasure": "Percentage of Pre-Dose FEV1", "timeFrame": "At two visits during a maximum of 15 days", "groups": [{"id": "OG000", "title": "Salbutamol pMDI", "description": "200 \u03bcg, inhalation, single dose"}, {"id": "OG001", "title": "Terbutaline Turbuhaler\u00ae", "description": "0.4 mg, inhalation, single dose"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "22"}, {"groupId": "OG001", "value": "22"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "113.59", "lowerLimit": "87.96", "upperLimit": "132.67"}, {"groupId": "OG001", "value": "117.05", "lowerLimit": "97.96", "upperLimit": "139.00"}]}]}]}, {"type": "SECONDARY", "title": "Maximum % Change in FEV1 (Forced Expiratory Volume in 1 Second) Within 4 Hours After Drug Inhalation", "description": "percent of pre-dose (ratio)", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Full Range", "unitOfMeasure": "Percent change", "timeFrame": "At two visits during a maximum of 15 days", "groups": [{"id": "OG000", "title": "Salbutamol pMDI", "description": "200 \u03bcg, inhalation, single dose"}, {"id": "OG001", "title": "Terbutaline Turbuhaler\u00ae", "description": "0.4 mg, inhalation, single dose"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "22"}, {"groupId": "OG001", "value": "22"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "122.62", "lowerLimit": "105.11", "upperLimit": "149.73"}, {"groupId": "OG001", "value": "121.43", "lowerLimit": "105.31", "upperLimit": "150.21"}]}]}]}, {"type": "SECONDARY", "title": "Time to Peak FEV1 (Forced Expiratory Volume in 1 Second) Within 4 Hours After Drug Inhalation", "description": "Time to peak measurement of FEV1 (min)", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Full Range", "unitOfMeasure": "Minutes", "timeFrame": "At two visits during a maximum of 15 days", "groups": [{"id": "OG000", "title": "Salbutamol pMDI", "description": "200 \u03bcg, inhalation, single dose"}, {"id": "OG001", "title": "Terbutaline Turbuhaler\u00ae", "description": "0.4 mg, inhalation, single dose"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "22"}, {"groupId": "OG001", "value": "22"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "60.00", "lowerLimit": "5.00", "upperLimit": "180.00"}, {"groupId": "OG001", "value": "120.00", "lowerLimit": "5.00", "upperLimit": "240.00"}]}]}]}, {"type": "SECONDARY", "title": "Number of Patients With % Change in FEV1 (Forced Expiratory Volume in 1 Second) >15% Within 4 Hours After Drug Inhalation", "description": "Number of patients with % change in FEV1 \\>15% within 4 hours after drug inhalation.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "At two visits during a maximum of 15 days", "groups": [{"id": "OG000", "title": "Salbutamol pMDI", "description": "200 \u03bcg, inhalation, single dose"}, {"id": "OG001", "title": "Terbutaline Turbuhaler\u00ae", "description": "0.4 mg, inhalation, single dose"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "22"}, {"groupId": "OG001", "value": "22"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "17"}, {"groupId": "OG001", "value": "16"}]}]}]}, {"type": "SECONDARY", "title": "Time to Change More Than or Equal to 15% (Time to Onset Response) Within 4 Hours After Drug Inhalation", "description": "Time to change more than or equal to 15% (time to onset response) within 4 hours after drug inhalation", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Minutes", "timeFrame": "At two visits during a maximum of 15 days", "groups": [{"id": "OG000", "title": "Salbutamol pMDI", "description": "200 \u03bcg, inhalation, single dose"}, {"id": "OG001", "title": "Terbutaline Turbuhaler\u00ae", "description": "0.4 mg, inhalation, single dose"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "22"}, {"groupId": "OG001", "value": "22"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "31.36", "spread": "37.49"}, {"groupId": "OG001", "value": "34.32", "spread": "40.31"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "eventGroups": [{"id": "EG000", "title": "Salbutamol pMDI", "description": "200 \u03bcg, inhalation, single dose.", "seriousNumAffected": 0, "seriousNumAtRisk": 23, "otherNumAffected": 0, "otherNumAtRisk": 23}, {"id": "EG001", "title": "Terbutaline Turbuhaler\u00ae", "description": "0.4 mg, inhalation, single dose.", "seriousNumAffected": 0, "seriousNumAtRisk": 23, "otherNumAffected": 0, "otherNumAtRisk": 23}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "LTE60", "restrictiveAgreement": true}, "pointOfContact": {"title": "Gerard Lynch", "organization": "AstraZeneca", "email": "ClinicalTrialTransparency@astrazeneca.com"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000000420", "term": "Albuterol"}, {"id": "D000013726", "term": "Terbutaline"}], "ancestors": [{"id": "D000001993", "term": "Bronchodilator Agents"}, {"id": "D000001337", "term": "Autonomic Agents"}, {"id": "D000018373", "term": "Peripheral Nervous System Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000018927", "term": "Anti-Asthmatic Agents"}, {"id": "D000019141", "term": "Respiratory System Agents"}, {"id": "D000015149", "term": "Tocolytic Agents"}, {"id": "D000012102", "term": "Reproductive Control Agents"}, {"id": "D000058666", "term": "Adrenergic beta-2 Receptor Agonists"}, {"id": "D000000318", "term": "Adrenergic beta-Agonists"}, {"id": "D000000322", "term": "Adrenergic Agonists"}, {"id": "D000018663", "term": "Adrenergic Agents"}, {"id": "D000018377", "term": "Neurotransmitter Agents"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000013566", "term": "Sympathomimetics"}], "browseLeaves": [{"id": "M3767", "name": "Albuterol", "asFound": "Upper limb", "relevance": "HIGH"}, {"id": "M16496", "name": "Terbutaline", "asFound": "Temodar", "relevance": "HIGH"}, {"id": "M5269", "name": "Bronchodilator Agents", "relevance": "LOW"}, {"id": "M20963", "name": "Anti-Asthmatic Agents", "relevance": "LOW"}, {"id": "M21137", "name": "Respiratory System Agents", "relevance": "LOW"}, {"id": "M17869", "name": "Tocolytic Agents", "relevance": "LOW"}, {"id": "M20746", "name": "Adrenergic Agents", "relevance": "LOW"}, {"id": "M3670", "name": "Adrenergic beta-Agonists", "relevance": "LOW"}, {"id": "M3673", "name": "Adrenergic Agonists", "relevance": "LOW"}, {"id": "M20504", "name": "Neurotransmitter Agents", "relevance": "LOW"}, {"id": "M16345", "name": "Sympathomimetics", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Repr", "name": "Reproductive Control Agents"}, {"abbrev": "Resp", "name": "Respiratory System Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}